The South Korean government has proposed expanding national health-insurance coverage to include medications used to treat hair loss [1].
The proposal has sparked a political debate over the ethical allocation of public health funds. Critics argue that using limited insurance resources for cosmetic concerns undermines the system's ability to treat life-threatening conditions.
Reform Party leader Lee Jun-seok criticized the plan, and said that the funds should instead be used to save patients with severe illnesses [1]. The government estimate for the cost of covering hair-loss drugs reaches several hundred billion won [1].
Opponents of the measure highlight the disparity in drug costs. Generic hair-loss medications typically cost between 10,000 and 30,000 won per month [1]. In contrast, drugs for rare diseases or targeted cancer treatments can cost tens of millions of won [1].
People Power Party policy chief Kim Mi-ae and Health Minister Jung Eun-kyung are among the officials involved in the ongoing discussions regarding the insurance scheme [1]. The debate comes as the national health-insurance finances are projected to run a deficit starting from 2024 onward [1].
Opposition leaders said that prioritizing hair-loss treatment is an inefficient use of taxpayer money during a financial downturn. They said that the insurance fund must prioritize those with the highest medical necessity to ensure the long-term sustainability of the healthcare system [1].
“The government estimate for the cost of covering hair-loss drugs reaches several hundred billion won.”
This conflict highlights a growing tension in South Korea between expanding social welfare to address quality-of-life issues and maintaining the fiscal solvency of the national healthcare system. As the insurance fund enters a deficit period, the government must decide if 'cosmetic' health is a right or a luxury, while the opposition seeks to protect the funding for high-cost, life-saving interventions.
